Open Actively Recruiting

Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors

About

Brief Summary

This is a first-in-human, Phase 1/2, multicenter, open-label study designed to evaluate the safety and tolerability of vilastobart (XTX101) as monotherapy and vilastobart (XTX101) and atezolizumab combination therapy in patients with advanced solid tumors.

Primary Purpose
Treatment
Study Type
Interventional
Phase
Phase 2

Eligibility

Gender
All
Healthy Volunteers
No
Minimum Age
18 Years
Maximum Age
N/A

Inclusion Criteria:

Exclusion Criteria:

Join this Trial

Share:
Study Stats
Protocol No.
24-5141
Category
Colorectal Cancer
Location
  • UCLA Santa Monica
For Providers
NCT No.
NCT04896697
For detailed technical eligibility, visit ClinicalTrials.gov.